News
MLAB
102.26
+1.51%
1.52
Weekly Report: what happened at MLAB last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at MLAB last week (0408-0412)?
Weekly Report · 04/15 09:24
25 GDP-sensitive Small-Cap stocks with low refinancing risk - BofA
25 GDP-sensitive Small-Cap stocks with low refinancing risk - BofA. Securities published the top 25 small-cap stocks that rank highly on GDP sensitivity and low on interest rates. Bof a analysts recommend investors focus on areas that can benefit from a GDP, commodity price, and manufacturing recovery.
Seeking Alpha · 04/12 17:43
Mesa Laboratories Enhances Financial Structure and Reduces Debt
TipRanks · 04/08 12:12
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES
Reuters · 04/08 12:00
Best Value Stocks to Buy for April 8th
NASDAQ · 04/08 10:16
Weekly Report: what happened at MLAB last week (0401-0405)?
Weekly Report · 04/08 09:26
Mesa Laboratories maintains quarterly dividend of $0.16
Mesa Laboratories, Inc. Maintains quarterly dividend of $0.16. Forward yield 0.64% Payable June 14; for shareholders of record May 31; ex-div May 30. The company has now announced a dividend of thirty-nine consecutive quarterly dividends.
Seeking Alpha · 04/05 04:58
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. Declares a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record on May 31, 2024. The company's Board of Directors has declared the dividend.
Barchart · 04/04 17:24
Mesa Labs Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 04/04 16:59
Mesa Labs Price Target Raised to $130.00/Share From $124.00 by Evercore ISI Group
Dow Jones · 04/04 16:59
Evercore ISI Group Maintains Outperform on Mesa Laboratories, Raises Price Target to $130
Benzinga · 04/04 16:48
Argosy Investors Q4 2023 Letter
Seeking Alpha · 04/03 12:40
Mesa Laboratories Expects Non-Cash Impairment Losses of $271M in 4Q
Mesa Laboratories expects to record non-cash impairment losses of about $271 million during the fourth quarter. Life science tools manufacturer says losses related to its clinical genomics and biopharmaceutical development divisions. Losses related to impairment testing of goodwill and other intangible assets.
Dow Jones · 04/02 18:03
*Mesa Laboratories, Inc.: In Addition, Expect to Record Non-cash Impairment Losses to Other Intangible Assets of Approximately $148M >MLAB
Dow Jones · 04/02 17:51
*Mesa Laboratories, Inc.: Currently Expect Unaudited Results for 4Q24 Will Include Non-Cash Impairment Losses of About $123M Related to Goodwill >MLAB
Dow Jones · 04/02 17:49
*Mesa Laboratories, Inc.: Expect to Record Non-Cash Impairment Losses Related to Clinical Genomics and Biopharmaceutical Development Divisions of About $271M During 4Q FY24 >MLAB
Dow Jones · 04/02 17:48
MESA LABORATORIES INC: NON-CASH ACCOUNTING CHARGES ARE NOT EXPECTED TO IMPACT CASH FLOWS FROM CURRENT OR FUTURE OPERATIONS
Reuters · 04/02 17:43
Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024
Barchart · 04/01 09:27
Weekly Report: what happened at MLAB last week (0325-0329)?
Weekly Report · 04/01 09:25
More
Webull provides a variety of real-time MLAB stock news. You can receive the latest news about Mesa Laboratories through multiple platforms. This information may help you make smarter investment decisions.
About MLAB
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.